BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38663675)

  • 1. Inhibition of human drug transporter activities by succinate dehydrogenase inhibitors.
    Kerhoas M; Le Vée M; Carteret J; Jouan E; Tastet V; Bruyère A; Huc L; Fardel O
    Chemosphere; 2024 Jun; 358():142122. PubMed ID: 38663675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of human hepatic cytochrome P-450 3A4 expression by antifungal succinate dehydrogenase inhibitors.
    Kerhoas M; Carteret J; Huchet L; Jouan E; Huc L; Vée ML; Fardel O
    Ecotoxicol Environ Saf; 2024 May; 276():116261. PubMed ID: 38574644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Drug Transporters and Drug Interactions.
    Ivanyuk A; Livio F; Biollaz J; Buclin T
    Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin.
    Chedik L; Bruyere A; Le Vee M; Stieger B; Denizot C; Parmentier Y; Potin S; Fardel O
    PLoS One; 2017; 12(1):e0169480. PubMed ID: 28099443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
    J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
    Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
    Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transporter-mediated Natural Product-Drug Interactions.
    Bi Y; Wang X; Ding H; He F; Han L; Zhang Y
    Planta Med; 2023 Feb; 89(2):119-133. PubMed ID: 35304735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of
    Parvez MM; Shin HJ; Jung JA; Shin JG
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
    [No Abstract]   [Full Text] [Related]  

  • 17. Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems.
    Lucero ML; Gonzalo A; Ganza A; Leal N; Soengas I; Ioja E; Gedey S; Jahic M; Bednarczyk D
    Drug Chem Toxicol; 2012 Jun; 35 Suppl 1():8-17. PubMed ID: 22616811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
    Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
    PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
    Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.